Dramatic tumor response of bulky liver metastases following treatment with CPT-11 and a chronomodulated 4-day infusion of 5-fluorouracil, folinic acid and oxaliplatin every 2 weeks in a colorectal cancer patient

Anti-Cancer Drugs

Volumn 11, Issue 4, 2000, Pages 263-268

  Gornet, Jean Marc ^a   Azoulay, Daniel ^a   Lévi, Francis ^a   Yovine, Alejandro ^a   Misset, Jean Louis ^a   Goldwasser, François ^a  

^a HÔPITAL PAUL BROUSSE   (France)

Author keywords

Chronomodulation; Colorectal cancer; CPT 11; Liver metastases; Oxaliplatin

Indexed keywords

FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; ARTICLE; BARIUM ENEMA; CASE REPORT; COLORECTAL CANCER; DEHYDRATION; DIARRHEA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LIVER METASTASIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; VOMITING;

ADENOCARCINOMA; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CHRONOTHERAPY; FEMALE; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; LEUCOVORIN; LIVER NEOPLASMS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; SIGMOID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 0034047868     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200004000-00006     Document Type: Article

References (34)

1. 1. Pommier Y, Pourquier P, Fan Y, et al. Mechanism of eukaryotic DNA toposiomerase I and drugs targeted to the enzyme. Biochim Biophys Acta 1998; 1400: 83-106.
2. 2. Raymond E, Faivre S, Woynarowski JM, et al. Oxaliplatin: mechanism of action and antineoplastic activity. Semin Oncol 1998; 25 (2, suppl 5): 4-12.
3. 3. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracil-based chemotherapy. J Clin Oncol 1997; 15: 251-60.
4. 4. Cunningham D, Pyrhonen S, James RD, et al. Randomized trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-8.
5. 5. Rougier P, Van Cutsem E, Bajetta E, et al. Randomized trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-12.
6. 6. Douillard JY, Cunningham D, Roth AD, et al. A randomized phase III trial comparing irinotecan+5FU/ folinic acid to the same schedule of 5FU/FA in patients with metastatic colorectal cancer as front line chemotherapy. Proc Am Soc Clin Oncol 1999; 18: 233a (abstr 899).
7. 7. Saltz LB, Locker PK, Pirotta N, et al. Weekly Irinotecan (CPT-11), Leucovorin (LV), and Fluorouracil (FU) is superior to daily x 5 LV/FU in patients (pts) with previously untreated metastic colorectal cancer (CRC). Proc Am Soc Clin Oncol 1999; 18: 233a (abstr 898).
8. 8. De Gramont A, Vignoud J, Tournigand C, et al. Oxaliplatin with high-dose leucovorin and 5-Fluorouracil 48-hour continous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997; 33: 214-9.
9. 9. Brienza S, Bensmaine MA, Soulie P, et al. Oxaliplatin added to 5-fluorouracil-based therapy (5-FU+FA) in the treatment of 5-FU-pretreated patients with advanced colorectal carcinoma (ACRC): results from the European compassionate-use program. Ann Oncol 1999; 10: 1311-6.
10. 10. André T, Louvet C, Raymond E, etal. Bimonthly high-dose leucovorin and 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen. Ann Oncol 1998; 9: 1251-3.
11. 11. André T, Bensmaine MA, Louvet C, et al. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen. J Clin Oncol 1999; 17: 3560-8.
12. 12. De Gramont A, Figer A, Seymour M, et al. A randomized trial of leucovorin and 5-fluorouracil with or without oxaliplatin in advanced colorectal cancer. Proc Am Soc Clin Oncol 1998; 17: 257a (abstr 985).
13. 13. Giacchetti S, Perpoint B, Zidani R, et al. Phase III multicenter randomized trial of oxaliplatin added to chronomodulated fluorouracil-leucovorin as first-line treatment of metastatic colorectal cancer. J Clin Oncol 2000; 18: 136-47.
14. 14. Wasserman E, Cuvier C, Lokiec F, et al. Combination of oxaliplatin plus irinotecan in patients with gastrointestinal tumors: results of two independent phase I studies with pharmacokinetics. J Clin Oncol 1999; 17: 1751-9.
15. 15. Goldwasser F, Gross M, Tigaud JM, et al. CPT-11/ oxaliplatin (L-OHP) combination every two weeks: final results of a phase I study in advanced digestive malignancies. Proc Am Soc Clin Oncol 1999; 18: 176a (abstr 675).
16. 16. Rothenberg ML, McKinney J, Hande KR, et al. A phase I clinical and pharmacokinetic trial of oxaliplatin and irinotecan (CPT-11) given every two weeks to patients with refractory solid tumors. Proc Am Ass Cancer Res NC1-EORTC 1999; abstr 614.
17. 17. Scheithauer W, Komek GV, Raderer M, et al. Combined irinotecan and oxaliplatin plus granulocyte colony-stimulating factor in patients with advanced fluoropyrimidine/ leucovorin-pretreated colorectal cancer. J Clin Oncol 1999; 17: 902-6.
18. 18. Bismuth H, Adam R, Lévi F, et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 1996; 224: 509-22.
19. 19. Bismuth H, Adam R. Reduction of nonresectable liver metastasis from colorectal cancer after oxaliplatin chemotherapy. Semin Oncol 1998; 25(2, suppl 5): 40-6.
20. 20. Giacchetti S, Itzhaki M, Gruia G, et al. Long-term survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin, and surgery. Ann Oncol 1999; 10: 663-9.
21. 21. Lévi F, Zidani R, Vannetzel JM, et al. Chronomodulated versus fixed-infusion-rate delivery of ambulatory chemotherapy with oxaliplatin, fluorouracil, and folinic acid (leucovorin) in patients with colorectal cancer metastases: A randomized multi-institutional trial. J Natl Cancer Inst 1994; 86: 1608-17.
22. 22. Raymond E, Buquet-Fagot C, Djelloul S, et al. Antitumor activity of oxaliplatin in combination with 5-fluorouracil and the thymidylate synthase inhibitor AG337 in human colon, breast and ovarian cancers. Anti-Cancer Drugs 1997; 8: 876-85.
23. 23. Zeghari-Squalli N, Raymond E, Cvitkovic E, Goldwasser F. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin. Clin Cancer Res 1999; 5: 1189-96.
24. 24. Zeghari-Squalli N, Misset JL, Goldwasser F. Mechanism of the in vitro interaction between SN-38 and 5-FU. Proc Am Ass Cancer Res 1997; 38: 3 (abstr 19).
25. 25. Lévi F, Zidani R, Misset J-L, et al. Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 1997; 350: 681-6.
26. 26. Abigerges D, Chabot GG, Armand JP, et al. Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210-21.
27. 27. Sastre J, Paz-Ares L, Diaz-Rubio E, et al. Phase I dose finding study of irinotecan (CPT-11) over a short iv infusion combined with a fixed dose of 5-Fluorouracil (5-FU) over a protracted iv infusion in patients (pts) with advanced solid tumors. Proc Am Soc Clin Oncol 1998; 18: 201a (abstr 775).
28. 28. Saltz L, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumors. J Clin Oncol 1996; 14: 2959-67.
29. 29. Comella P, Casaretti R, De Vita F, et al. Concurrent irinotecan and 5-fluorouracil plus levo-folinic acid given every other week in the first-line management of advanced colorectal carcinoma: a phase I study of the Southern Italy Cooperative Oncology Group. Ann Oncol 1999; 10: 915-21.
30. 30. Vanhoefer U, Harstrick A, Kohne CH, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999; 17: 907-13.
31. 31. Ducreux M, Ychou M, Seitz JF, et al. Irinotecan combined with bolus fluorouracil, continous infusion fluorouracil, and high-dose leucovorin every two weeks (LV5FU2 regimen): A clinical dose-finding and pharmacokinetic study in patients with pretreated metastatic colorectal cancer. J Clin Oncol 1999; 17: 2901-8.
32. 32. Rothenberg ML, Pazdur R, Rowinsky EK, et al. A phase II multicenter trial of alternating cycles of irinotecan and 5FU/LV in patients with previously untreated metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 266a (abstr 944).
33. 33. Barone C, Pozzo C, Starkhammar H, et al. CPT-11 alternating with 5-FU/folinic acid: a multicentre phase II study in first line chemotherapy of metastatic colorectal cancer. Proc Am Soc Clin Oncol 1997; 16: 270a (abstr 957).
34. 34. Lévi F, Giacchetti S. Chronomodulation of chemotherapy against metastatic colorectal cancer. In: Bleiberg H, eds. Management of colorectal cancer. Philadelphia, PA: Lippincott 1998; 27: 289-306.